A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Bb 2121 (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 24 Oct 2018 Status changed from recruiting to not yet recruiting.
- 18 Oct 2018 Status changed from not yet recruiting to recruiting.
- 06 Sep 2018 Status changed from planning to not yet recruiting.